Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 11, 2009, Pages 1678-1685

  Storr, Martin A ^a   Keenan, Catherine M ^b   Zhang, Hong ^b   Patel, Kamala D ^b   Makriyannis, Alexandros ^c   Sharkey, Keith A ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

AM1241; AM630; Cannabinoid 2 receptor; Colitis; Inflammatory bowel disease; JWH133; TNBS

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; COMPLEMENTARY DNA; DEXTRAN SULFATE; MESSENGER RNA; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COLON; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; ENZYME ACTIVITY; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; WILD TYPE;

ANIMALS; CANNABINOIDS; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; INDOLES; INFLAMMATORY BOWEL DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; RECEPTOR, CANNABINOID, CB2;

EID: 72549108949     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20960     Document Type: Article

References (30)

1. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.
2. Raitio KH, Salo OM, Nevalainen T, et al. Targeting the cannabinoid CB2 receptor: mutations, modeling and development of CB2 selective ligands. Curr Med Chem. 2005;12:1217-1237.
3. Izzo AA, Mascolo N, Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol. 2001;1:597-603.
4. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med. 2005;83:944-954. (Pubitemid 41745753)
5. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut. 2001;48:859-867.
6. Storr M, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007;7:575-582.
7. Storr M, Yuce B, Goeke B. Perspectives of cannabinoids in gastroenterology. Z Gastroenterol. 2006;44:185-191.
8. D'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J. 2006;20:568-570. (Pubitemid 46671252)
9. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202-1209.
10. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol. 2006;291:G364-G371.
11. 2 receptors. J Mol Med. 2008;86:925-936.
12. Duncan M, Mouihate A, Mackie K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol. 2008;295:G78-G87.
13. Buckley NE, McCoy KL, Mezey E, et al. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol. 2000;396:141-149.
14. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology. 1989;96:795-803.
15. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol. 1990;258:G527-G534.
16. Bradley PP, Christensen RD, Rothstein G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood. 1982;60:618-622.
17. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344-1350.
18. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84-87. (Pubitemid 30143137)
19. Huffman JW, Liddle J, Yu S, et al. 3-(1′,1′-Dimethylbutyl)-1- deoxydelta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem. 1999;7:2905-2914. (Pubitemid 30105863)
20. Ibrahim MM, Deng H, Zvonok A, et al. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 2003;100:10529- 10533.
21. Sibaev A, Massa F, Yuce B, et al. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med. 2006;84:513-520.
22. 2 like cannabinoid receptors on peripheral nerve terminals. Eur J Pharmacol. 1997;339:53-61.
23. Storr M, Gaffal E, Saur D, et al. Effect of cannabinoids on neural transmission in rat gastric fundus. Can J Physiol Pharmacol. 2002;80:67-76. (Pubitemid 34194288)
24. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263-270.
25. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology. 2005;129:437-453. (Pubitemid 41096632)
26. Kimball ES, Palmer JM, D'Andrea MR, et al. Acute colitis induction by oil of mustard results in later development of an IBS-like accelerated upper GI transit in mice. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1266-G1273.
27. Thuru X, Chamaillard M, Karsak M, et al. Cannabinoid receptor 2 is required for homeostatic control of intestinal inflammation. Gastroenterology. 2007;132(suppl 2):A228.
28. Ziring DA, Braun J. AM1241, a CB2-specific agonist protects against immune but not acute colitis. Gastroenterology. 2007;132(suppl 2):A232.
29. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol. 2003;7:469-475.
30. Dziadulewicz EK, Bevan SJ, Brain CT, et al. Naphthalen-1-yl-(4- pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB(1)/CB(2) dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem. 2007;50:3851-3856.